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The apparent association of rheumatoid arthritis (RA) with
the MHC region and, in particular, with the shared epitope
present in the peptide-binding cleft of certain DR mole-
cules has always amazed me. It is amazing because it sug-
gests a narrow specificity of immune responses in RA
whereas other observations suggest there should not be.
Nevertheless, it is one of the few clear and unarguable
findings that give us one end of a thread to unwind this
complex disease. The MHC association was discovered
decades ago and has been the subject of numerous inves-
tigations, but the mechanism is still not known. In fact,
there is no indisputable evidence for which MHC gene or
genes is responsible for the association. This is the time of
unraveling the entire human genome sequence and,
accordingly, there are expectations to find the genes that
control our most common diseases. The MHC region was
the first to be sequenced but this did not elucidate the
mystery of its genes. Still, there are good candidates and,
in fact, the shared epitope hypothesis gives strong argu-
ments for a role of the DR molecule. It is under dispute
whether other class II molecules are involved, such as DQ,
or even other MHC molecules, such as tumor necrosis
factor a, but let us say that the DR molecule (in particular,
specific structures in its peptide binding pocket) does play
an important role in the disease.
So, what does that mean? Several mechanisms have been
proposed, all supported by circumstantial evidence (sum-
marized in Fig. 1). Some of these thoughts and arguments
[1–4] are collected in this Arthritis Research issue. All
accept the role of the shared epitope of the DR molecule
but, in Taneja and David’s view [1], the role of the DR mol-
ecule is rather to deliver peptides to be bound to the DQ
molecule. The shared epitope peptide fails to bind to the
disease associated DQ molecules, which are then avail-
able to bind self-peptides of importance for the develop-
ment of arthritis. Thus, DQ is the disease-associated
molecule, as supported by mouse experiments, in which
the expression of DQ8 is permissive for development of
collagen induced arthritis (CIA). This is opposed by
Fugger and Svejgaard [2], who argue that there is no evi-
dence for a role for DQ in RA and that the expression of
DR1 and DR4, with shared epitope, in mice also permits
the development of CIA. However, neither of the alterna-
tives, DR or both DR and DQ, directly explains the role of
MHC in RA, although they cast some light on the mouse
model of CIA.
It is easy to be enthusiastic about the possibility of directly
humanizing animal models but I think there are reasons to
treat them with great caution. The insertion of foreign
genes will certainly give erroneous results that are easy to
accept if they fit our thinking but difficult to explain if they
do not. The mouse models will, however, give significant
information by themselves. In the mouse model, it has
been shown that a bottleneck in the pathogenesis is the
T cell response to an immunodominant peptide bound to
the murine Aq molecule, a finding reproduced by the
human DR1 and DR4 which, in fact, have quite similar
peptide-binding pockets. It leaves important questions,
such as those about tolerance of collagen-reactive T cells
and the downstream effector pathways, but it definitely
provides a workable model. This model may, however,
have little to do with RA or may reflect only one of the
many pathways that can lead to RA. Weyand and Goronzy
[3] point out one very important fact about RA, which
tends to be forgotten in discussing mechanisms — that RA
is most likely not a disease, but a syndrome that could be
caused by many different diseases. This needs clearly to
be taken into account when discussing the role of MHC.
Thus, different DR alleles seem to be associated with dif-
ferent subforms of RA. And this is probably only the begin-
ning of the dissection of RA in different specific diseases
controlled by various sets of genes.Arthritis Research    Vol 2 No 3 Holmdahl
Thus, there is room for different mechanisms for how the
MHC is involved in the pathogenesis of RA. One, very
attractive, such explanation is the shaping of the T cell
repertoire as proposed by Roudier [4]. Specific DR alleles
do have an impact on the T cell repertoire and so have
specific combinations of peptides bound to class II, which
provides room for several attractive possibilities of cross-
reactive responses to peptides from various infectious
organisms. However, these connections need to be proven.
Also, the role of a skewed T cell repertoire needs to be for-
mulated and shown, although numerous experiments in
experimental systems demonstrate the importance of regu-
latory cells selected in the thymus. Experimental models for
RA are needed to test this point. Unfortunately, the
presently used limited number of animal models has failed
to show an importance of at least the genetically selected
polymorphism of the T cell repertoire [5], but there are still
experimental systems in which a somatic selected repertoire
could be of importance [6]. However, as in all investigations
of the pathogenesis of RA, it is difficult to sort out the hen
and the egg, and the RA process in itself clearly results in a
contracted T cell repertoire [7].
The solution of the MHC enigma is a Gordian knot in
understanding RA, and it is still far from being cut. The role
of MHC alleles in the subtypes of RA definitely needs to
be known more precisely, and also the role at different
phases of the disease. Maybe their role is to determine the
self-perpetuative events rather than the susceptibility as
such or, alternatively, to control the downstream effector
phases of the disease. Such differences have been
observed not only in RA, but also in various animal models
[8,9]. Ways are also needed to directly address and prove
our hypotheses. Some animal models, like CIA, have sug-
gested a clearer proposal that needs to be challenged,
and workable models for other hypotheses also need to
be developed in order to test these possibilities. In this
way we can further our understanding and improve our
attempts at therapy for the various subsets of RA.
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Figure 1
Some of the mechanisms proposed for the role of DR in RA. (a) DR
molecules provides peptides for binding to other MHC molecules
which will trigger T cells that regulate pahogenic T cells. (b) DR- self
peptide complexes select the T cell repertoire that may have a
regulatory impact on the activation of pathogenic T cells. (c) DR
molecules bind self peptides, which may or may not be derived from
joint tissue, that trigger pathogenic T cells. (d) Another possibility is
that DR molecules binds peptides derived from infectious agents that
may persist in the joints or give rise to a self cross-reactive T cells.
Subsequently the activated T cells could induce, modulate or regulate
the erosive destruction of the joints.
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